NCT07347977Not yet recruiting
Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk
Lidocaine Infusion Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk: a Multicenter Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 16 Jan 2026
Brief summary (registry, in English)
The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients. Participants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg/kg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg/kg/h (calculated as 1-1.5 mg/kg/h in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 1400 (estimated)
- First submitted
- 5 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 30 Sept 2029
- Lead sponsor
- First Affiliated Hospital of Ningbo University
- Diseases
- Lung cancer
- NCT number
- NCT07347977
What you commit to
- Study type: Interventional
- Planned participants: 1400
- From 1 Jan 2026 to the primary completion date, 30 Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Palliative surgery without intention of cure.
- Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).
- Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.
Other illness
- Patients with known or suspected allergy to lidocaine.
- Epilepsy.
Lab values
- Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.
- Currently, there is severe renal insufficiency (serum creatinine ≥451umol/L or glomerular filtration rate (calculated using the MDRD formula) \<30ml/min).
- Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.
Other
- Extensive comorbidities (ASA IV).
- Patients who are currently pregnant or breastfeeding.
- Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.
- Patients with body weight \<40kg
Who the study is looking for
- Age range: 18-80 years old.
- Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer
- Is willing and capable of providing consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Ningbo University Coordinator of this site? Confirm its status | Ningbo | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.